中生製藥(01177.HK)治療神經病理性疼痛藥物已向美國提交試驗用新藥申請並獲受理

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

中生製藥(01177.HK)治療神經病理性疼痛藥物已向美國提交試驗用新藥申請並獲受理

阿思達克 09-25 08:18

中國生物製藥(01177.HK)公佈，其自主研發的「TRD205 (AT2R拮抗劑)」已向美國食品藥品監督管理局(FDA)提交試驗用新藥(IND)申請並獲得受理。 TRD205爲血管緊張素II型2受體(AT2R)的新型拮抗劑，擬開發用於治療神經病理性疼痛。

中国生物制药(01177.HK)

Relevant Stocks

中国生物制药(01177.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

中生製藥(01177.HK)治療神經病理性疼痛藥物已向美國提交試驗用新藥申請並獲受理

Services

About Us

Agreement Statement